Society for Immunotherapy of Cancer (SITC)’s Post

Three New Clinical Trials of Immunotherapy for Pancreatic Ductal Adenocarcinoma Beginning at Siteman Cancer Center. Principal investigator David G. DeNardo, PhD, is a Washington University professor of medicine and Siteman Cancer Center research member. He is a leading researcher in the national, multi-institutional effort working to identify more effective pancreatic cancer treatments. “Already, research has contributed to improved survival rates for subsets of pancreatic cancer patients, but we think we can do much better.” Learn more about this Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Click > https://lnkd.in/g76tTnTm

📢 Exciting News from Oncology Research! 🚀 Thrilled to announce the release of our latest issue, Volume 32.1! 🌐✨ Dive into cutting-edge research and explore new dimensions in cancer studies. Here are some captivating articles that await your attention: 1️⃣ "New perspectives on biology, disease progression, and therapy response of head and neck cancer gained from single cell RNA sequencing and spatial transcriptomics." 2️⃣ "Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment." 3️⃣ "Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy." And many more! 🚀 Dive into the diverse world of oncology research and stay at the forefront of advancements. 🌟 Embark on a journey of discovery with Oncology Research! 🚀🔬 Don't miss out on the latest insights. Read, share, and be part of the conversation! 🌟📚 #OncologyResearch #CancerResearch #NewDiscoveries #ScientificAdvancements Read the full articles and stay updated: https://lnkd.in/gSvVUpFM

Come and see the latest in kidney cancer translational, basic and clinical research - Toni Choueiri KidneyCAN Bryan Lewis Sumanta Pal, MD, FASCO Rana McKay Ari Hakimi Thomas Powles,MD #Cancer #ClinicalResearch #KCRS24 #KidneyCancer #KidneyCAN #OncoDaily #Oncology

Recently, the research paper "The Future of Affordable Cancer Immunotherapy" was published, featuring contributions from Professor Michal Lotem and her collaborators from various medical institutions. The article discusses innovative strategies to make #cancer  #immunotherapy  more accessible and cost-effective. It explores leveraging the antigenicity of "cold tumors" using affordable reagents, using microbiome-based products, making adoptive cell therapy more affordable, and employing RNA-based therapeutic cancer vaccines. The article also examines the use of a limited set of predictive biomarkers instead of extensive sequencing and explores affordable immunohistochemistry markers to guide individual therapies. The goal is to improve the cost-benefit ratio of cancer immunotherapy, making it a viable option for more patients globally. Professor Michal Lotem is the Head of the Center for #Melanoma and Cancer Immunotherapy at Hadassah University Hospital. #cancertreatment Full text article: https://lnkd.in/ersYUgtZ

evitria’s journal club - paper of the week no. 28 Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer Zuhair Chaudhry et al. (2024) Breast cancer research is evolving! 🌟 This review highlights the potential of neoantigens—tumor-specific antigens resulting from genetic alterations—as promising targets for personalized immunotherapy. Key biomarkers like TP53, Survivin, PALB2, and PTPRT show significant potential. Despite challenges in timely delivery and accessibility, neoantigen-based therapies could revolutionize breast cancer treatment, offering hope for improved patient outcomes 💪 Developing the next cancer breakthrough? Get in touch with our scientists to learn how we can support you: www.evitria.com/contact   #BreastCancerResearch #Immunotherapy #Neoantigens

In recent years, there has been a transformative shift in the field of oncology with the emergence of cancer #immunotherapy as a novel approach to #cancer treatment. Unlike conventional methods like chemotherapy or radiation, which directly target cancer cells, immunotherapy utilizes the body's immune system to combat and eliminate cancer. Our case study “Developing personalised immunotherapies for cancer” showcases the pioneering research conducted by Professor Vincenzo Cerullo and his team at the ImmunoViroTherapy Lab at University of Helsinki. This groundbreaking work resulted in the establishment of the spin-out company Valo Therapeutics Ltd (ValoTx), aimed at enhancing the efficacy and accessibility of cancer immunotherapy for patients. Read here 👉 https://lnkd.in/eXr7RBgu EU Science, Research and Innovation #innovation #research #HorizonResultsPlatform #H2020 #HorizonEU

June marks the beginning of Cancer Immunotherapy Month, an annual campaign we are proud to support. Gera Goverse, Director, Immuno-Oncology, gives her reflections on cancer immunotherapy as an innovative approach, offering new hope and possibilities for patients worldwide. At Crown Bioscience, our mission is to empower our customers to improve human health. We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation. We are utilizing our large patient-derived organoid biobank, which includes almost 100 models validated in co-culture assays with immune cells, so newly developed immunotherapies can be tested preclinically. These models thereby contribute to the improvement of clinical success of cancer patients. Join us this month as we continue to share recent advancements, preclinical resources, and explore the future of cancer immunotherapy together. Learn more about us ➡️https://hubs.la/Q02zhZDt0 #Immunotherapy #Immune2Cancer #CancerResearch Cancer Research Institute (CRI)

We are very pleased to announce the appointment to our Scientific Advisory Board of Jeffrey. S. Weber, M.D., Ph.D., Deputy Director of the Perlmutter Cancer Center and Co-Director of the Melanoma Research Program at the New York University-Langone Cancer Center.   Dr. Weber’s work has led to groundbreaking achievements in cancer immunotherapy. He brings extensive research and clinical experience which we look forward to drawing on as we continue to develop our novel Selected TIL-based pipeline and progress our lead clinical program, TIDAL-01, for people with solid tumors.   To read the press release, please visit => https://lnkd.in/gVaUZY-r   #SelectedTILs #TILtherapy #tumorinfiltratinglymphocytes #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cellimmunotherapy #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #tsbx #opportunities #people #leadership #biotechnology #cellandgenetherapy

This National Cancer Research Month, we celebrate the remarkable efforts of researchers worldwide who have transformed the oncology landscape. Exciting news has emerged with two CAR-T cell therapies gaining FDA approvals for earlier-line use in patients with multiple myeloma. Johnson & Johnson and Legend Biotech’s therapy Carvykti was approved as a second-line treatment, while Abecma, developed by Bristol Myers Squibb and 2seventy bio, was approved as a third-line treatment.  This means CAR-T therapy will become more accessible to patients who can benefit from these treatments earlier— and that will save lives. It’s innovations like these that motivate us to continue supporting researchers who are pushing the boundaries of cancer research. With our portfolio of products and services, we’re providing the tools that make a real difference in the fight against cancer.  #cartcelltherapy #multiplemyeloma #immunotherapy   https://lnkd.in/eVFxvePn  

Following October as Breast Cancer awareness month, November is Carcinoid Cancer, Gastric Cancer, Lung Cancer and Pancreatic Cancer (PDAC) awareness month. Together with my collaborator Nadine Laguette we are happy that our recent publication regarding the future of STING as target opportunity in PDAC has been highlighted by Elsevier's Cancer Letters. Less prominent in numbers than other types of cancer, PDAC is unfortunately nearly to 100% lethal, steadily increasing in incidence (unlike other cancers which decrease) and with no targeted therapy in sight. More (national) funding is needed, especially for high-risk translational research projects in general. The funding organisms have to stop "playing safe" with funding predictable research projects detached from any application in the near future. Patients are waiting, we have no time to loose: we need biomarker signatures and lead compounds now.